VSX2

Across TCGA pan-cancer cohorts, VSX2 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of VSX2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where VSX2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types VSX2 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

LIHC, LUAD, and HNSC are the cancer types where VSX2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in VSX2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.011	.004	4	view →
LUAD	Female	III,IV	−0.161	.028	2	view →
HNSC	All	All	+0.023	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

VSX2–LIHC

Open the LIHC breakdown →